The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 13, 2023
Filed:
Jul. 20, 2018
Genentech, Inc., South San Francisco, CA (US);
Foundation Medicine, Inc., Cambridge, MA (US);
Craig Anthony Cummings, South San Francisco, CA (US);
Yan Li, South San Francisco, CA (US);
Sarah Margaret Shagan, South San Francisco, CA (US);
Erica Beth Schleifman, South San Francisco, CA (US);
David Shames, South San Francisco, CA (US);
David Fabrizio, Cambridge, MA (US);
Daniel Lieber, Cambridge, MA (US);
Geoffrey Alan Otto, Cambridge, MA (US);
Mark Kennedy, Cambridge, MA (US);
Travis Clark, Cambridge, MA (US);
Doron Lipson, Cambridge, MA (US);
Jie He, Cambridge, MA (US);
Shan Zhong, Belmont, MA (US);
Genentech, Inc., South San Francisco, CA (US);
Foundation Medicine, Inc., Cambridge, MA (US);
Abstract
The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.